AVEO Pharmaceuticals (AVEO) Stock Research, Analysis & News

Quick Analysis on AVEO Pharmaceuticals (AVEO) Stock as of March 25, 2017

Previous Closing Price $0.71 is below its 50 day moving average $0.79
Previous Closing Price $0.71 is below its 200 day moving average $0.72
The Stock pays no dividend
The closing price $0.71 is more than 235.21% away from its one year target price of $2.38
Current Short Ratio 4.25 is great than 1
Earning per Share $-0.44 is negative. AVEO Pharmaceuticals is lossing money.
EBITDA $-26.09M is negative
It is a very small cap stock with market cap of $50.83M
(See more information about AVEO Pharmaceuticals (AVEO) Stock below)

AVEO Pharmaceuticals (AVEO) Stock Profile Summary

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The companys lead product candidate, Tivozanib (AV-951), is a novel, highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2, and 3. It is also leading the clinical development of AV-299, which includes conducting multiple Phase I clinical trials and preparing for the conduct of multiple Phase II clinical trials. The companys product candidate in preclinical development is AV-203, a potent ErbB3 antibody that has demonstrated efficacy in vivo. It has strategic partnerships with OSI Pharmaceuticals, Inc., Merck, and Biogen Idec, Inc. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded in 2001 and is based in Cambridge, Massachusetts.

AVEO Pharmaceuticals (AVEO) Stock Key Statistics Research and Analysis as of March 25, 2017

Stock ExchangeNMS
Market Capitalization$50.83M
Trade Volume (Average Trading Volume)765,158 (325,969)
Price/Sales9.06
Price/Book15.20
Earning/Share$-0.44
Current Year EPS Estimate$-0.43
Next Year EPS Estimate$-0.43
Previous Closing Price$0.71
50 Day Price Moving Average$0.79
200 Day Price Moving Average$0.72
1 yr Target Price$2.38
PEG Ratio0.00
Short Ratio4.25
EBITDA$-26.09M

AVEO Pharmaceuticals (AVEO) Stock Competitor Research and Analysis

Pfizer Inc. (PFE)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Stock Research on AVEO Pharmaceuticals (AVEO)

Latest Market News on AVEO Pharmaceuticals (AVEO)


Click here to find the latest news on AVEO Pharmaceuticals (AVEO)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Pfizer Inc. (PFE)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)